Introduction
============

In 2001, an Expert Panel was convened at the request of the Food and Agriculture Organization of the United Nations, and supported by the World Health Organization, to clarify the definition of probiotics. The resultant publication defined probiotics as "Live microorganisms which when administered in adequate amounts confer a health benefit on the host" ([@B14]). In 2014, a consensus panel reiterated the definition, with one small change replacing "which" with "that" ([@B25]).

Since 2001, scientific investigation of probiotics has grown substantially. As of February 11, 2019, there were 20,315 papers indexed to the term "probiotic" compared to 760 papers prior to 2001. Commercially, the sales of probiotics are over \$40 billion and are projected to reach over \$64 billion by 2023 ([@B21]).

The probiotic field represents the translational potential of microbiology to humans and animals. Despite well characterized mechanisms for microbial therapies to affect a number of organ systems in the host, confusion persists around the precise conditions necessary for a single microbe or microbial consortia to claim probiotic effect (verb) or qualify as a probiotic (noun). Specifically, a set of guidelines stipulates the need for both microbial strain designation and for at least one human study to be performed on the target host to be considered probiotic ([@B14]). Liberal and loose usage of the term has resulted in confusion and as a result, probiotics have collectively garnered a degree of global skepticism. The aim of this article is to clarify the term probiotics and urge researchers to employ precision and consistency in both their investigations and communication of data pertaining to microbes for human health.

Illustrating the Problems
=========================

A physician wanting to provide a patient with advice on preventing traveler's diarrhea (TD) may have referenced a recent meta-analysis by [@B2] regarding the use of probiotics as a treatment. This publication used a seemingly appropriate inclusion criteria of double-blind, placebo-controlled, randomized human trials with TD as an outcome, and various statistical methods to conclude that probiotics were efficacious in preventing TD. However, a closer look at the listed interventions shows one study that utilized dead lactobacilli and two other studies that included the administration of prebiotics. Caution must be exercised when interpreting such data, given that probiotics must be live ([@B14]; [@B50]), and the definition of a prebiotic is "a substrate that is selectively utilized by host microorganisms conferring a health benefit" ([@B20]).

Confusion within the field is not restricted to meta-analyses. Conclusions are often advanced based on improperly designed intervention studies that extrapolate broad generalizations from a limited data set. Several examples are worth citing. One study concentrating on the use of probiotics in acute pancreatitis suggested that they contributed to bacterial translocation and enterocyte damage in organ failure ([@B4], [@B5]). Yet, there is no direct evidence that the administered strains were the cause ([@B48]). Aside from the issue of whether or not this is an appropriate clinical setting to administer extrinsic living bacteria, the study's conclusion has been enlarged to imply that any or all probiotics might adversely impact all patients with pancreatitis. Nine years later, that initial study has been fully reassessed concluding that probiotics are not contraindicated in pancreatitis. The prior negative outcomes were related to unexpected lactic acidosis from the fermentation of carbohydrates ([@B8]). Indeed, this more recent study recommended starting probiotics immediately upon diagnosis, massively increasing the probiotic dose, and limiting fermentable carbohydrates.

To avoid unwarranted damage to the reputation of probiotics, stringent testing and careful clinical guidelines are imperative in the treatment and management of high risk adults and children ([@B51]). Not all centers have avoided use of probiotics in seriously ill patients as a result of the pancreatitis paper, and indeed one site has reported substantial benefits in treating seriously ill trauma patients with probiotics or synbiotics ([@B19]). Furthermore, there is clear evidence of probiotics as useful in preventing necrotizing enterocolitis in premature, low-birth weight babies which is certainly a critically ill patient sub-set ([@B44]).

Another pertinent example of the over interpretation of limited data is a recent study conducted on 34 patients suffering from "brain fogginess," which is a set of presentations including impaired concentration, confusion, and poor short-term memory ([@B47]). Based on the observation that consumption of fermented food or commercially available microbial products was a shared trait amongst the patients reporting brain fog, the study implied that all probiotics could be causative agents of brain fogginess. While the definition of probiotics accommodates strains of any taxa, it is unlikely that these included the *Streptococcus*, *Staphylococcus*, *Neisseria*, or *Hemophilus*, which were the primary organisms detected by culture in the duodenal aspirates. Furthermore, 68% of the cohort presented with small intestinal bacterial overgrowth (SIBO) and there were no data to verify patients were acidotic; a crucial linkage considering many lactobacilli and all bifidobacteria only produce [L]{.smallcaps}-lactate and not [D]{.smallcaps}-lactate ([@B61]; [@B45]; [@B46]). In the future, appropriate trial design can strengthen the field by moving away from observational and correlative data sets. In this case, the study concluded that probiotics may be causative of brain fog on the observation that antibiotic therapy alleviated symptoms of brain fog, whereas a more appropriately designed study would have split the patients after antibiotic therapy into two groups, and upon reintroduction of probiotics in a defined cohort, compared the emergence of symptoms against the antibiotic-treated control.

In a third example, a recent study suggesting probiotics impair naïve microbiota recovery after antibiotic therapy concluded that probiotics may be harmful to the gut microbiota when administered after antibiotic use ([@B56]). In this instance, [@B56] performed an intervention study on healthy subjects given high doses of metronidazole and ciprofloxacin. The subjects received evacuation therapy twice in 28 days so that intestinal samples could be acquired. Based on the observation that 10--15 species had a longer recovery time compared to spontaneous recovery and autologous fecal microbiota transplantation (aFMT), the study put forward the thesis that probiotic consumption may present latent danger to the gut microbiome and, by extension, the host. There are serious limitations to asserting broad generalizations from one narrow data set to the field as a whole. In this case, two subsequent human studies published within a month of the [@B56] study and a second report from that group ([@B68]) presented alternative data ([@B10]; [@B36]). The first demonstrated that probiotic supplementation restored normal microbiota composition and function in antibiotic-treated and cesarean-born infants. A second study examined a different microbial preparation and its effect on microbiome recovery after antibiotic therapy ([@B10]). Notably, the microbial intervention contained a 700% higher dosage and was administered for twice the intervention period as the [@B56] intervention with opposite data showing improved microbiome alpha-diversity in the "probiotics" group as measured by the Shannon diversity index, a heterogeneity measure that combines richness and evenness components of microbial diversity ([@B10]). It is worth noting that all three publications were released in the same month, yet the results of one were extrapolated to the field as a whole, hindering an open scientific dialog on the advantages or limitations of probiotics or their reproducible effects based on strain specificity.

Relevantly, it is worth nothing that one should not rely on metagenomic and 16s rRNA data as an endpoint alone, but rather monitor clinical and functional outcomes, for example an increase in short-chain fatty acid production and their direct immunological effect on colonic Treg cells ([@B54]) and other pathological processes ([@B9]; [@B26]; [@B41]). Another effect of well characterized probiotic strains is to confirm protection of the intestinal epithelium, in some cases reversing damage caused by antibiotics ([@B49]).

The Minimal Requirements for the Evaluation of an Effective Probiotic
=====================================================================

As indicated in the original [@B14] report, there are certain expectations required to call an organism "probiotic." These have been further clarified in 2014 ([@B25]), and clearly must include:

The definition of probiotics as "Live microorganisms, that when administered in adequate amounts, confer a health benefit on the host."

1.  That microbes must be alive in an adequate number when administered.

2.  Strains must be identified genetically, classified using the latest terminology, and designated by numbers, letters, or names.

3.  Appropriately sized and designed studies must be performed to designate a strain as probiotic and using the strain(s) on the host to which the probiotics are intended (human, livestock, companion animal, etc).

4.  Strains shown to confer a benefit for one condition may not be probiotic for another application.

5.  Strains that are probiotic for humans but are being used in animal studies should be clearly designated as human probiotics under experimental testing.

Fermented foods, prebiotics, fecal microbiota transplant, and microbial strains of the same genus or species as documented probiotic strains but have not undergone appropriate testing on the target host should not be considered as probiotics based on adherence to the scientific definition.

Guidance for Physicians
=======================

Within the field of microbiome science, the rate of discovery of novel organisms with potentially therapeutic benefit for the human host is progressing rapidly. Emerging research on microbial strains includes some with systemic immunomodulatory activity ([@B18]), the prevention and treatment of food allergies ([@B31]; [@B15]), modulation of the gut-liver axis ([@B3]), production of neuroactive metabolites ([@B60]), and inhibitory activity against infectious microbes in the gut ([@B30]), skin ([@B34]), and urogenital tract ([@B22]). Furthermore, microbes are now understood as integral to an extensive number of essential metabolic processes ([Table 1](#T1){ref-type="table"}) ([@B24]; [@B37]; [@B1]; [@B29]; [@B40]; [@B12]; [@B57]; [@B58]; [@B16]; [@B23]; [@B38]; [@B39]; [@B42]; [@B43]; [@B65]; [@B52]; [@B55]; [@B59]; [@B64]; [@B66]; [@B6]; [@B35]; [@B63]; [@B13]; [@B17]; [@B53]; [@B67]). From these discoveries will emerge new microbial-based interventions.

###### 

Physiological and metabolic processes influenced by the human microbiome.

  Processes                                                                                              Reference
  ------------------------------------------------------------------------------------------------------ ------------------------
  Enzymatic pathways, glycosaminoglycan degradation                                                      [@B1]; [@B35]
  Energy metabolism (short chain fatty acids, glucose)                                                   [@B12]; [@B23]; [@B55]
  Neurotransmitter production                                                                            [@B43]; [@B65]; [@B52]
  Vitamin absorption                                                                                     [@B38]
  Regulation of bile acid metabolism, (deoxycholic and lithocholic acids, bile salts)                    [@B16]; [@B63]
  Endocrine and gut hormone regulation                                                                   [@B42]; [@B17]
  Adaptive immunity, mucosal and systemic immunity                                                       [@B59]; [@B13]
  Cell proliferation, mucosal barrier protection, inflammation                                           [@B40]; [@B6]; [@B53]
  Protection against pathogens                                                                           [@B66]; [@B67]
  Vascularization, tri-ethylamine associated atherosclerosis, tri-ethylamine N-oxide (TMAO) production   [@B29]; [@B57]; [@B58]
  Bone mass                                                                                              [@B39]; [@B64]
  Appetite signaling, obesity                                                                            [@B24]; [@B37]
  Metabolic transformation of xenobiotics (small molecules foreign to the body)                          [@B35]
                                                                                                         

Therefore, it is expected that the misuse of the term "probiotic" to describe any microbe with plausible therapeutic utility in the human host may persist unless there is strict adherence to the requirements of an exacting definition. To the extent that physicians may require guidance for evaluating the merits of current and future microbial preparations, three key elements in determining the validity of a probiotic are proposed:

1.  Evidence that the strain(s) has been tested in a randomized, controlled or equivalent human trial, in either a heterogeneous population or stratified based on defined characteristics of host or microbial genomics.

2.  The dose and viability in the product are equal to that of the human trial(s).

3.  Whole genome strain characterization and transparently declared strain designation are provided.

If a strain is selected for a specific mechanism, such as being able to upregulate gut barrier proteins, and is then tested in humans and shown to improve gut barrier function leading to a health benefit ([@B28]), then inclusion of that strain at the tested dose would be expected to convey the same outcome even in the presence of other strains. An example is *B. breve* BR03 being selected for immunomodulatory and gut barrier function activities and consequently being found in a 300-person study to increase Treg cells, or in 49 children with Celiac disease to decrease TNFα production ([@B11]; [@B33]).

Studies of the human microbiome have established that despite significant interpersonal variation at the species level, many core metabolic functions are maintained amongst individuals in a population ([@B7]; [@B32]; [@B62]). Therefore, as the field of personalized medicine gains traction, it is important that proponents of individualized therapies clearly define the basis for population stratification, and demonstrate efficacy for the proposed personalized therapy in the specific subpopulation being targeted. A more universal approach would entail the discovery and validation of microbes with significant and reproducible effects across a heterogeneous population. Therapies under both a stratified and heterogeneous population would meet the guidelines of probiotic, provided the impact on human health is established in a controlled human trial.

Future Directions
=================

Research investigating microbial administration to, or modulation of, the human microbiome to improve health has been progressing at a rapid rate since the term probiotics was defined in 2001. It has been amplified by the Human Microbiome Project and sustained by the interdisciplinary efforts beyond microbiology that have contributed to the velocity of microbiome research worldwide. It comes at a time where there has never been a greater appreciation for the microbes that inhabit life-forms and the planet. The potential to manipulate these microbial ecosystems offers great hope for new preventive and treatment options for many diseases. The idea that ingesting or administering live microbes can serve therapeutic functions is gaining prominence, but just as too many microbiome studies in rodents and humans "oversell" their limited findings ([@B27]), too much misinformation has stemmed from misuse of the probiotic term. It is hoped that the fundamental principles outlined herein, that encourage adherence to a strict scientific definition of "probiotics" and rigorous assessment of their actual clinical outcomes will assert greater clarity and foster a deeper understanding within this dynamic field.
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